Opinion: How artificial intelligence can bolster Europe’s competitive edge in biopharma
In a year marked by European Parliament elections and setting of the European Union’s priorities…
Category: Pharmaceuticals
STAT+: How to tell if Biden drove a hard bargain on drug prices
WASHINGTON — The deadline for announcing how much Medicare lowered drug prices in the first…
New cardiovascular risk model could greatly decrease use of statins and increase heart attacks, study warns
If up to half of Americans no longer qualify for a statin or a blood…
STAT+: How Pfizer’s grand gene therapy ambitions crumbled
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for…
STAT+: The state pharma’s targeting this election cycle
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for…
STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say
Amid concerns that the pharmaceutical industry abuses the U.S. patent system, a new paper suggests…
STAT+: House hearing keeps pressure on PBM practices while Congress considers reforms
The House Oversight Committee kept pressure on drug middlemen at a hearing today that focused…
STAT+: European Commission reaches deal with Vifor for ‘disparaging’ its only rival in iron deficiency market
Following a two-year probe, the European Commission has formalized a proposal from Vifor Pharma to…
STAT+: Here come Medicare’s first negotiated drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Novartis hedges on when it might submit myelofibrosis drug for approval
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the…
STAT+: A second Roche obesity drug shows promise in early studies
LONDON — Roche on Wednesday reported positive early data from another of the obesity drug…
STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down
A clutch of headlines last week suggested the U.S. Senate had achieved a breakthrough in…
Sen. Menendez’s conviction may cost pharma a key ally in Congress
A New York jury on Tuesday found Sen. Bob Menendez guilty on 16 counts for…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pfizer says it will advance once-daily GLP-1 pill after all
Pfizer said that it plans to advance a new once-a-day formulation of its experimental obesity…
STAT+: Novo Nordisk’s weekly insulin rejected by FDA
The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes…
STAT+: FTC plans to sue PBMs over the high cost of insulin and other medicines, reports say
The U.S. Federal Trade Commission reportedly plans to sue the three largest pharmacy benefit managers…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The pharmaceutical industry keeps losing Washington friends
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down
Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills
The Biden administration has appealed a decision in which a federal court jury last year…
.jpg)
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to…
STAT+: U.K. trade group scolds Novo, Novartis, Pfizer and Otsuka for violating industry codes
Four large drugmakers — Novartis, Pfizer, Novo Nordisk, and Otsuka Pharmaceutical — were scolded by…
Study links Ozempic to higher risk of eye condition that can cause vision loss
A new observational study on Wednesday reported for the first time a potential link between…
GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership
GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control…
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents
The U.S. Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to…
STAT+: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines
The owners of a drug wholesaler have been indicted for their alleged role in a…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Upending Purdue Pharma’s settlement does little to help today’s opioid crisis, advocates say
The drug policy world has been left torn by the Supreme Court’s ruling on Thursday…
Listen: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy? And what health…
STAT+: Walgreens could shutter hundreds of underperforming stores
Walgreens is finalizing a plan to fix its U.S. business that could result in closing…
Exclusive: European VC Forbion hires Dyne CEO, expands into US
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Intellia says its CRISPR-based therapy can be redosed
Want to stay on top of the science and politics driving biotech today? Sign up to get…
One firm, two conflicting takes on Alnylam’s HELIOS-B
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer
Pharmaceutical companies in the U.K. have increasingly violated a voluntary industry marketing code but complaints…
The findings from Alnylam’s highly anticipated readout
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests
WASHINGTON — A House panel is exploring holding a vote on scaled-back versions of two…
STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more
And so, another working week will soon draw to a close. Not a moment too…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Doctors Without Borders is closing its widely regarded access-to-medicines campaign
In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
To treat obesity in children, task force favors behavioral therapy over drugs like Wegovy
A national advisory organization has come down on the side of behavioral interventions, not obesity…